<?xml version='1.0' encoding='utf-8'?>
<document id="26248122"><sentence text="Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection." /><sentence text="We reviewed the most recent data on pharmacokinetic interactions between hepatitis C direct-acting antiviral (DAA) agents and HIV antiretrovirals (ARVs)" /><sentence text="" /><sentence text="Drug interactions between DAAs and HIV ARVs are extrapolated from phase 1 drug-drug interaction (DDI) studies in healthy volunteers" /><sentence text=" Safety and efficacy data of DAA-ARV combinations are largely limited to the drug combinations permitted in phase 2 and 3 HIV-HCV coinfection trials" /><sentence text=" Paritapervir/ritonavir with ombitasvir and dasabuvir (3D) should not be coadministered with efavirenz, etravirine, elvitegravir/cobicistat or with additional doses of ritonavir"><entity charOffset="1-13" id="DDI-PubMed.26248122.s6.e0" text="Paritapervir" /><entity charOffset="14-23" id="DDI-PubMed.26248122.s6.e1" text="ritonavir" /><entity charOffset="29-39" id="DDI-PubMed.26248122.s6.e2" text="ombitasvir" /><entity charOffset="44-53" id="DDI-PubMed.26248122.s6.e3" text="dasabuvir" /><entity charOffset="93-102" id="DDI-PubMed.26248122.s6.e4" text="efavirenz" /><entity charOffset="104-114" id="DDI-PubMed.26248122.s6.e5" text="etravirine" /><entity charOffset="116-128" id="DDI-PubMed.26248122.s6.e6" text="elvitegravir" /><entity charOffset="168-177" id="DDI-PubMed.26248122.s6.e7" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e0" e2="DDI-PubMed.26248122.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e0" e2="DDI-PubMed.26248122.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e0" e2="DDI-PubMed.26248122.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e0" e2="DDI-PubMed.26248122.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e0" e2="DDI-PubMed.26248122.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e0" e2="DDI-PubMed.26248122.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e0" e2="DDI-PubMed.26248122.s6.e6" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e0" e2="DDI-PubMed.26248122.s6.e7" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e1" e2="DDI-PubMed.26248122.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e1" e2="DDI-PubMed.26248122.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e1" e2="DDI-PubMed.26248122.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e1" e2="DDI-PubMed.26248122.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e1" e2="DDI-PubMed.26248122.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e1" e2="DDI-PubMed.26248122.s6.e6" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e1" e2="DDI-PubMed.26248122.s6.e7" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e2" e2="DDI-PubMed.26248122.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e2" e2="DDI-PubMed.26248122.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e2" e2="DDI-PubMed.26248122.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e2" e2="DDI-PubMed.26248122.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e2" e2="DDI-PubMed.26248122.s6.e6" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e2" e2="DDI-PubMed.26248122.s6.e7" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e3" e2="DDI-PubMed.26248122.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e3" e2="DDI-PubMed.26248122.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e3" e2="DDI-PubMed.26248122.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e3" e2="DDI-PubMed.26248122.s6.e6" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e3" e2="DDI-PubMed.26248122.s6.e7" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e4" e2="DDI-PubMed.26248122.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e4" e2="DDI-PubMed.26248122.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e4" e2="DDI-PubMed.26248122.s6.e6" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e4" e2="DDI-PubMed.26248122.s6.e7" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e5" e2="DDI-PubMed.26248122.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e5" e2="DDI-PubMed.26248122.s6.e6" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e5" e2="DDI-PubMed.26248122.s6.e7" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e6" e2="DDI-PubMed.26248122.s6.e6" /><pair ddi="false" e1="DDI-PubMed.26248122.s6.e6" e2="DDI-PubMed.26248122.s6.e7" /></sentence><sentence text=" Atazanavir, darunavir and rilpivirine require cautious monitoring when used with 3D"><entity charOffset="1-11" id="DDI-PubMed.26248122.s7.e0" text="Atazanavir" /><entity charOffset="13-22" id="DDI-PubMed.26248122.s7.e1" text="darunavir" /><entity charOffset="27-38" id="DDI-PubMed.26248122.s7.e2" text="rilpivirine" /><pair ddi="false" e1="DDI-PubMed.26248122.s7.e0" e2="DDI-PubMed.26248122.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26248122.s7.e0" e2="DDI-PubMed.26248122.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26248122.s7.e0" e2="DDI-PubMed.26248122.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26248122.s7.e1" e2="DDI-PubMed.26248122.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26248122.s7.e1" e2="DDI-PubMed.26248122.s7.e2" /></sentence><sentence text=" The combination of sofosbuvir and ledipasvir can be safely used with most ARVs, but there is a risk of hyperbilirubinaemia with atazanavir"><entity charOffset="20-30" id="DDI-PubMed.26248122.s8.e0" text="sofosbuvir" /><entity charOffset="35-45" id="DDI-PubMed.26248122.s8.e1" text="ledipasvir" /><entity charOffset="129-139" id="DDI-PubMed.26248122.s8.e2" text="atazanavir" /><pair ddi="false" e1="DDI-PubMed.26248122.s8.e0" e2="DDI-PubMed.26248122.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26248122.s8.e0" e2="DDI-PubMed.26248122.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26248122.s8.e0" e2="DDI-PubMed.26248122.s8.e2" /><pair ddi="false" e1="DDI-PubMed.26248122.s8.e1" e2="DDI-PubMed.26248122.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26248122.s8.e1" e2="DDI-PubMed.26248122.s8.e2" /></sentence><sentence text=" Tenofovir exposure is significantly increased when used with sofosbuvir-ledipasvir and a boosted protease inhibitor or emtricitabine/efavirenz, and therefore should be used with cautious monitoring for renal toxicity only when alternative therapy is not possible"><entity charOffset="1-10" id="DDI-PubMed.26248122.s9.e0" text="Tenofovir" /><entity charOffset="62-72" id="DDI-PubMed.26248122.s9.e1" text="sofosbuvir" /><entity charOffset="73-83" id="DDI-PubMed.26248122.s9.e2" text="ledipasvir" /><entity charOffset="120-133" id="DDI-PubMed.26248122.s9.e3" text="emtricitabine" /><entity charOffset="134-143" id="DDI-PubMed.26248122.s9.e4" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.26248122.s9.e0" e2="DDI-PubMed.26248122.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26248122.s9.e0" e2="DDI-PubMed.26248122.s9.e1" /><pair ddi="false" e1="DDI-PubMed.26248122.s9.e0" e2="DDI-PubMed.26248122.s9.e2" /><pair ddi="false" e1="DDI-PubMed.26248122.s9.e0" e2="DDI-PubMed.26248122.s9.e3" /><pair ddi="false" e1="DDI-PubMed.26248122.s9.e0" e2="DDI-PubMed.26248122.s9.e4" /><pair ddi="false" e1="DDI-PubMed.26248122.s9.e1" e2="DDI-PubMed.26248122.s9.e1" /><pair ddi="false" e1="DDI-PubMed.26248122.s9.e1" e2="DDI-PubMed.26248122.s9.e2" /><pair ddi="false" e1="DDI-PubMed.26248122.s9.e1" e2="DDI-PubMed.26248122.s9.e3" /><pair ddi="false" e1="DDI-PubMed.26248122.s9.e1" e2="DDI-PubMed.26248122.s9.e4" /><pair ddi="false" e1="DDI-PubMed.26248122.s9.e2" e2="DDI-PubMed.26248122.s9.e2" /><pair ddi="false" e1="DDI-PubMed.26248122.s9.e2" e2="DDI-PubMed.26248122.s9.e3" /><pair ddi="false" e1="DDI-PubMed.26248122.s9.e2" e2="DDI-PubMed.26248122.s9.e4" /><pair ddi="false" e1="DDI-PubMed.26248122.s9.e3" e2="DDI-PubMed.26248122.s9.e3" /><pair ddi="false" e1="DDI-PubMed.26248122.s9.e3" e2="DDI-PubMed.26248122.s9.e4" /></sentence><sentence text=" Daclatasvir requires dosage modification with atazanavir, efavirenz and cobicistat"><entity charOffset="1-12" id="DDI-PubMed.26248122.s10.e0" text="Daclatasvir" /><entity charOffset="47-57" id="DDI-PubMed.26248122.s10.e1" text="atazanavir" /><entity charOffset="59-68" id="DDI-PubMed.26248122.s10.e2" text="efavirenz" /><entity charOffset="73-83" id="DDI-PubMed.26248122.s10.e3" text="cobicistat" /><pair ddi="false" e1="DDI-PubMed.26248122.s10.e0" e2="DDI-PubMed.26248122.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26248122.s10.e0" e2="DDI-PubMed.26248122.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26248122.s10.e0" e2="DDI-PubMed.26248122.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26248122.s10.e0" e2="DDI-PubMed.26248122.s10.e3" /><pair ddi="false" e1="DDI-PubMed.26248122.s10.e1" e2="DDI-PubMed.26248122.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26248122.s10.e1" e2="DDI-PubMed.26248122.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26248122.s10.e1" e2="DDI-PubMed.26248122.s10.e3" /><pair ddi="false" e1="DDI-PubMed.26248122.s10.e2" e2="DDI-PubMed.26248122.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26248122.s10.e2" e2="DDI-PubMed.26248122.s10.e3" /></sentence><sentence text=" The coadministration of simeprevir with efavirenz, etravirine or ritonavir-boosted and cobicistat-boosted regimens is not recommended"><entity charOffset="25-35" id="DDI-PubMed.26248122.s11.e0" text="simeprevir" /><entity charOffset="41-50" id="DDI-PubMed.26248122.s11.e1" text="efavirenz" /><entity charOffset="52-62" id="DDI-PubMed.26248122.s11.e2" text="etravirine" /><entity charOffset="66-75" id="DDI-PubMed.26248122.s11.e3" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.26248122.s11.e0" e2="DDI-PubMed.26248122.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26248122.s11.e0" e2="DDI-PubMed.26248122.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26248122.s11.e0" e2="DDI-PubMed.26248122.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26248122.s11.e0" e2="DDI-PubMed.26248122.s11.e3" /><pair ddi="false" e1="DDI-PubMed.26248122.s11.e1" e2="DDI-PubMed.26248122.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26248122.s11.e1" e2="DDI-PubMed.26248122.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26248122.s11.e1" e2="DDI-PubMed.26248122.s11.e3" /><pair ddi="false" e1="DDI-PubMed.26248122.s11.e2" e2="DDI-PubMed.26248122.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26248122.s11.e2" e2="DDI-PubMed.26248122.s11.e3" /></sentence><sentence text="" /><sentence text="The safety and efficacy of HCV therapy in HIV-HCV coinfection is now comparable with HCV monoinfection, but drug interactions need to be carefully considered before instituting therapy to minimize potential harm" /><sentence text=" Real-world data are required to further assess the clinical implications of some DDIs" /><sentence text="" /></document>